Key facts
- Notable investors include CAS Investment Management, Hankang Capital, Capital Science and Technology Development Group, Chang Development, Zhongguancun Development Group — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Benewill
- ·The full record, as it builds
Funding rounds
No funding rounds for Benewill are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Benewill
Developer of innovative drugs and vaccines intended to cure infectious disease. The company focuses on researching and developing viral protein structure biology and antibody epitopes, the research of infectious disease infection and immune mechanism, and focuses on the development of infectious disease, tumor vaccines and therapeutic antibody drugs, enabling advanced infection treatment for medical applications.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2021
- Website
- benewill.com/
- Ownership
- Privately Held (backing)
Benewill doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Benewill shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Benewill in its N-PORT filings yet. We sweep new filings monthly.